Status:
COMPLETED
Oligosaccharide for Cdiff(+) Heme-onc Patients
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Clostridium Difficile
Hematologic Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clostridium difficile causes \~453,000 infections and \~29,300 deaths per year in the US, making it the most common hospital acquired infection in the country. C. difficile is an anaerobic bacterium t...
Detailed Description
Aim 1/Objective 1. Establish the feasibility of oligosaccharide supplementation and twice a week stool collections among 12 C. difficile colonized hematology-oncology inpatients. It will be determined...
Eligibility Criteria
Inclusion
- Patients must meet all inclusion criteria to be eligible to participate in the study.
- Patients must be at least 18 years of age at time of consent.
- Positive C. difficile surveillance test.
- Absence of diarrhea or abdominal pain within the past 48 hours.
- Patient admitted in a hematology-oncology unit which for the purposes of this study will be defined as 7-CFAC and 8-CFAC.
Exclusion
- Patients must NOT meet any exclusion criteria to be eligible to participate in the study.
- Presence of \>= grade I nausea/vomiting.
- Inability to take oral medications or food.
- Expected length of hospitalization or survival less than 5 days
- Patient is only boarding in hematology-oncology units and would have not otherwise been admitted to these units.
- Unwillingness or inability to provide written informed consent.
- Women known to be pregnant or lactating during the study.
- History of inflammatory bowel disease.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03778606
Start Date
June 1 2019
End Date
August 1 2021
Last Update
October 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226